Immix Biopharma Inc (IMMX)
1.56
-0.03
(-1.89%)
USD |
NASDAQ |
Sep 27, 16:00
1.50
-0.06
(-3.85%)
After-Hours: 20:00
Immix Biopharma Enterprise Value: 18.85M for Sept. 27, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 27, 2024 | 18.85M |
| September 26, 2024 | 19.67M |
| September 25, 2024 | 21.32M |
| September 24, 2024 | 21.04M |
| September 23, 2024 | 22.14M |
| September 20, 2024 | 25.44M |
| September 19, 2024 | 24.61M |
| September 18, 2024 | 24.89M |
| September 17, 2024 | 25.71M |
| September 16, 2024 | 26.81M |
| September 13, 2024 | 27.08M |
| September 12, 2024 | 25.79M |
| September 11, 2024 | 27.08M |
| September 10, 2024 | 28.18M |
| September 09, 2024 | 30.10M |
| September 06, 2024 | 30.10M |
| September 05, 2024 | 33.67M |
| September 04, 2024 | 31.28M |
| September 03, 2024 | 32.02M |
| August 30, 2024 | 34.77M |
| August 29, 2024 | 34.22M |
| August 28, 2024 | 36.96M |
| August 27, 2024 | 35.87M |
| August 26, 2024 | 35.32M |
| August 23, 2024 | 35.04M |
| Date | Value |
|---|---|
| August 22, 2024 | 36.69M |
| August 21, 2024 | 38.61M |
| August 20, 2024 | 35.59M |
| August 19, 2024 | 33.40M |
| August 16, 2024 | 28.18M |
| August 15, 2024 | 27.91M |
| August 14, 2024 | 28.46M |
| August 13, 2024 | 27.08M |
| August 12, 2024 | 26.81M |
| August 09, 2024 | 29.51M |
| August 08, 2024 | 30.88M |
| August 07, 2024 | 31.98M |
| August 06, 2024 | 35.00M |
| August 05, 2024 | 35.82M |
| August 02, 2024 | 34.72M |
| August 01, 2024 | 33.08M |
| July 31, 2024 | 32.80M |
| July 30, 2024 | 37.74M |
| July 29, 2024 | 33.90M |
| July 26, 2024 | 37.47M |
| July 25, 2024 | 35.00M |
| July 24, 2024 | 32.53M |
| July 23, 2024 | 33.63M |
| July 22, 2024 | 36.09M |
| July 19, 2024 | 33.08M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-6.471M
Minimum
Nov 10 2022
124.73M
Maximum
Dec 15 2023
29.04M
Average
22.14M
Median
Sep 23 2024
Enterprise Value Benchmarks
| CEL-SCI Corp | 66.64M |
| AIM ImmunoTech Inc | 8.574M |
| IGC Pharma Inc | 25.09M |
| NovaBay Pharmaceuticals Inc | 3.420M |
| Protalix BioTherapeutics Inc | 52.61M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.393M |
| Total Expenses (Quarterly) | 4.702M |
| EPS Diluted (Quarterly) | -0.15 |
| Earnings Yield | -53.85% |